Janssen’s golimumab Simponi® under safety surveillance

Aug 11, 2020

Docwirenews reports a new post-approval safety surveillance study of Janssen’s golimumab Simponi® demonstrated that there is no association between exposure to golimumab and an increased risk of prespecified outcomes.

Print Page Mail Article